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Abstract Human retinal gene 4 (HRG4) (UNC119) is a photo-
receptor synaptic protein of unknown function, shown when
mutated to cause retinal degeneration in a patient and in a
con¢rmatory transgenic model. ADP-ribosylation factor-like
protein 2 (ARL2) was identi¢ed as an interactor of HRG4 by
the yeast two-hybrid strategy. The presence of ARL2 in the
retina and co-localization with HRG4 was con¢rmed by West-
ern blot and double immuno£uorescence analysis, respectively.
The interaction of ARL2 with HRG4 was further con¢rmed by
co-immunoprecipitation and direct binding analysis. Phospho-
diesterase N (PDEN) is an ARL2-binding protein homologous
to HRG4. Amino acid residues of PDEN involved in binding
ARL2 and forming a hydrophobic pocket were shown to be
highly conserved in HRG4, suggesting similarity in binding
mechanism and function.
0 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Human retinal gene 4 (HRG4) is a photoreceptor synaptic
protein, originally isolated in our laboratory by a subtractive
cDNA cloning strategy designed to isolate cDNAs speci¢c to
or enriched in the retina [1,2]. HRG4 is the ¢rst synaptic
protein to be described that is highly enriched in the photo-
receptor synapse, both of rods and cones. HRG4 appeared to
be predominantly associated with synaptic vesicles in the pho-
toreceptor synapses [2]. It is orthologous to UNC119 in Cae-
norhabditis elegans which was isolated in mutant nematodes
with defects in coordination, feeding, and chemosensation [3].
A truncation mutation in HRG4 was discovered in a patient
with late-onset cone^rod dystrophy, and a transgenic model
expressing the same mutation was shown to develop late-onset
retinal degeneration as did the human patient, accompanied
by severe synaptic and trans-synaptic degeneration [4]. Specif-
ic changes in retinal synaptic proteins were demonstrated in
the transgenic model before the onset of obvious pathology,
including a decrease in peripheral membrane proteins of the
synaptic vesicle [5]. Judging from its localization to the syn-
aptic vesicles and the e¡ect of the mutation on the synapse/
synaptic vesicle proteins, the function of HRG4 appeared to
involve the normal homeostasis of photoreceptor synaptic
vesicles and their associated proteins.
The yeast two-hybrid technology has been a powerful tool
in identifying the targets of many novel proteins, thereby elu-
cidating or providing valuable clues as to the function of the
protein [6,7]. In order to understand the function of HRG4,
we determined the identity of its interacting protein(s) by the
yeast two-hybrid strategy. A retinal cDNA prey library was
constructed and used to identify the correct tissue-speci¢c
interactor for HRG4. As a result, ADP-ribosylation factor
(ARF)-like protein 2, ARL2, was identi¢ed. The interaction
between HRG4 and ARL2 was con¢rmed in in vitro experi-
ments and shown to be similar to that between a homologous
protein, phosphodiesterase N (PDEN), and ARL2. Co-locali-
zation of HRG4 and ARL2 in the retina was also demon-
strated.
2. Materials and methods
2.1. Yeast two-hybrid system
Hybrid Hunter1 Two-Hybrid System (Invitrogen, Carlsbad, CA,
USA) was used in this study. The yeast strain used was L40 (MATK
his3v200trp1-901 leu2-3112 ade2 LYS2: :4lexAop-His3 URA3: :8lex-
Aop-lacZ GAL4).
2.2. Construction of interactive trap (prey) cDNA library
40 Wg of phage DNA was extracted from human retinal cDNA
clones [8] using the Lambda Maxi Kit (Qiagen, Valencia, CA,
USA), and the inserts were cut out. Inserts between the sizes of 500
bp and 5 kb were cut out from the gel after electrophoresis, and
isolated using the QIAquick Gel Extraction Kit (Qiagen). 100 ng of
inserts was ligated into 100 ng of digested, directional prey library
plasmid (pYESTrp2). 10 Wl out of 20 Wl of the ligation mixture was
used for transformation into Escherichia coli XL-10-Gold ultracom-
petent cells (Stratagene, La Jolla, CA, USA). 80 000 primary clones
were obtained and used for the large transformation. Average size of
the inserts was 1.7 kb (data not shown).
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2.3. Construction of the bait yeast strain
The bait plasmid pHybLex/Zeo-HRG4 was constructed by ligating
a polymerase chain reaction (PCR)-derived fragment (PCR primers;
pHyb-1, 5P-CCGGAATTCATGAAGGTGAAGAAGGGCGGCG-3P,
pHyb-2, 5P-ATGGGCTTGACTGGGGACACCA-3P, 901 bp prod-
uct) encoding the complete amino acid sequence of HRG4 (5P end
beginning at the initiation codon ATG (position 55 in the cDNA
sequence) with a 9 bp built-in EcoRI restriction site and the 3P end
at position 946 in the cDNA sequence just after a KpnI site) into
pHybLex/Zeo that had been digested with EcoRI and KpnI. The liga-
tion reaction was performed with 80 ng of pHybLex/Zeo and 78 ng of
inserts in a total reaction volume of 20 Wl. 1 Wl of the ligation mixture
was used for transformation into XL-1 blue (Stratagene) competent
bacteria. Construction of the bait plasmid (pHybLex/Zeo-HRG4) was
con¢rmed by sequencing, and 4 Wg of the bait plasmid was trans-
formed into L40 yeast strain using the S.c. EasyComp Kit (Invitro-
gen). Expression of the HRG4 protein in the yeast was con¢rmed by
enhanced chemiluminescence (ECL)1 Western blotting (Amersham,
Piscataway, NJ, USA). In brief, zeocin-resistant transformants (puta-
tive bait strain) and untransformed L40 were cultured overnight, cen-
trifuged, and the aqueous phase was decanted. The cell pellets were
placed in a 380‡C freezer for 10 min, thawed in 100 Wl of pre-warmed
(360‡C) cracking bu¡er, and transferred to a 1.5 ml microcentrifuge
tube containing 100 Wl of glass beads. The solution was incubated at
370‡C for 10 min, vortexed for 1 min, and centrifuged at 14 000 rpm
for 5 min at room temperature. 50 Wl of the supernatant was used for
immunoblot analysis. Antibody used to assay the level of fusion pro-
tein expression was the polyclonal anti-LexA antibody (Invitrogen)
and a polyclonal anti-rat RRG4 antibody [2]. Further con¢rmation
was performed to determine that the bait clone does not show proto-
trophy for histidine (to con¢rm the absence of contamination by other
yeast strains or leakage of expression of histidine-related genes, L40
being auxotrophic for histidine), and it does not show L-galactosidase
activity (to con¢rm the absence of non-speci¢c transactivation of the
reporter construct in the L40 strain) (data not shown).
2.4. Large-scale transformation and screening
500 Wg of interactive trap cDNA clones (prey library) was large-
scale transformed into the bait strain according to the manufacturer’s
protocol. In brief, the L40 strain containing the bait was cultured
overnight at 30‡C and centrifuged. The pellets were washed with
Tris^ethylenediamine tetraacetic acid (TE) and mixed with lithium
acetate/0.55UTE. 500 Wg of prey cDNA was mixed with 1 ml of
salmon sperm DNA, added to the cell suspension, and incubated
with lithium acetate/40% polyethylene glycol (PEG)/TE at 30‡C for
30 min. After addition of 17.6 ml dimethyl sulfoxide (DMSO), the
mixture was heat shocked at 42‡C for 6 min. After several washes
with the yeast extract peptone dextrose medium, the cells were sus-
pended in 10 ml of medium. 100 Wl of the suspension was plated out
in 40 plates and incubated at 30‡C for 2^4 days. Clones were picked
and arranged in a grid on new plates for easy manipulation of the
L-galactosidase ¢lter lifting assay. Positive colonies were detected by
selecting on plates lacking the auxotrophic marker (histidine), fol-
lowed by a second screen for L-galactosidase activity by ¢lter lifting
assay in addition to the zeocin selection. Plasmids encoding the puta-
tive interactors were retrieved according to the manufacturer’s proto-
col. Brie£y, an overnight culture of a positive yeast clone was mixed
with the lysis bu¡er, vortexed with glass beads, extracted with phenol/
chloroform, centrifuged, and the aqueous phase was ethanol precipi-
tated to obtain the DNA. The plasmid DNA was resuspended in 25 Wl
of TE, and transformed into E. coli (XL-1 blue) with ampicillin se-
lection in order to obtain only the pYEST plasmid, not the bait
plasmid. All double-selected colonies were identi¢ed by DNA se-
quencing. To eliminate the possibility of false positives, the L40 yeast,
transformed with each putative positive interactor clone, was tested
for expression of L-galactosidase by the ¢lter lifting assay as is, or
after additional transformation with the bait vector, bait vector con-
taining HRG4, and bait vector containing lamin. A true positive clone
showed the blue color only when the putative interactor clone and the
HRG4-containing bait vector were present together.
2.5. Antibody production
All procedures using animals were conducted in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Polyclonal antibody against ARL2 was produced
using recombinantly expressed human ARL2 as previously described
for rat HRG4 (RRG4) antibody [2]. Brie£y, glutathione-S-transferase
(GST)-ARL2 hybrid protein was expressed from a pGEX clone con-
taining the PCR-ampli¢ed human ARL2 sequence, and ARL2 was
separated from the GST protein by thrombin digestion. 500 Wg of
ARL2 was injected into rabbit with complete and incomplete Freunds
adjuvant in three di¡erent doses over 4 weeks, and serum was col-
lected over a total of 9 weeks. The activity of the antiserum was
con¢rmed by Western blotting of expressed ARL2. The antiserum
was a⁄nity-puri¢ed by chromatography through ARL2-bound Seph-
arose 4B. The speci¢city of the antibody for ARL2 was tested by
inactivation of the antibody activity by mixing with excess ARL2
antigen and use in Western blot analysis of expressed ARL2.
2.6. Preparation of retinal protein extracts
Rat and mouse retinas were homogenized in bu¡er containing 50
mM Tris^HCl (pH 8),150 mM NaCl, 0.02% sodium azide, 100 Wg/ml
phenylmethylsulfonyl £uoride, 1 Wg/ml aprotinin, and 1% Triton
X-100 and centrifuged at 10 000Ug for 10 min at 4‡C. Protein con-
centration of the supernatant was measured by the modi¢ed Lowry
method (Micro Protein Determination; Sigma, St. Louis, MO, USA).
2.7. Western blotting
10^30 Wg of protein samples was suspended in the same volume of
sample bu¡er (50 mM Tris^HCl (pH 6.8), 100 mM dithiothreitol, 2%
sodium dodecyl sulfate (SDS), 0.1% bromophenol blue, and 10%
glycerol), incubated at 95‡C for 5 min, and electrophoresed in Tris^
tricine SDS^polyacrylamide gel (SDS^PAGE). The proteins in the gel
were transferred to polyvinylidene di£uoride (PVDF) ¢lters (Milli-
pore, Bedford, MA, USA) by electroblotting. After the transfer, the
polyacrylamide gels were stained with Coomassie blue to visualize the
remaining proteins and size markers. The ¢lters were blocked in 4 ml
of PBST bu¡er (phosphate-bu¡ered saline (PBS) with 0.1% Tween 20)
supplemented with 0.1% non-fat dry milk for 1 h with gentle shaking
at room temperature, rinsed twice, and washed three times with 150
ml each of fresh PBST. The blots were incubated with the ARL2
(1:200) or RRG4 (1:100) antibody for 1 h, washed, reacted with
horseradish peroxidase-conjugated goat anti-rabbit antibody, washed,
and processed for detection by enhanced chemiluminescence (ECL;
Amersham).
2.8. Preparation of frozen sections
5 months old rats were killed, and eyes were enucleated. Incisions
were made around the limbus, and the eyes were ¢xed in 4% para-
formaldehyde in 0.1 M phosphate bu¡er for 2 h, followed by soaking
in 20% sucrose in 0.1 M phosphate bu¡er overnight. Before section-
ing, the eyes were embedded in OCT (Miles, Elkhart, IN, USA) and
frozen in liquid nitrogen. 6 Wm sections were cut on a cryostat and
kept dry at 320‡C until used.
2.9. Immuno£uorescence
6 Wm frozen sections of the rat retinas were analyzed by double
immuno£uorescence with polyclonal antibodies to human ARL2 and
rat HRG4 (RRG4) [2] as described before [9]. Brie£y, the frozen
sections were dried at room temperature for 20 min, blocked over-
night with blocking bu¡er (10% goat serum, 1% bovine serum albu-
min (BSA), 0.1% Triton X-100 in PBS, pH 7.4), and incubated with
the ¢rst primary antibody, ARL2, in PBS at a dilution of 1:50 for 90
min. After three washes in PBS, the sections were incubated with the
secondary antibody (£uorescein isothiocyanate (FITC)-labeled goat
anti-rabbit IgG; Sigma) at a dilution of 1:50 for 30 min, followed
by three washes in PBS. Then the sections were post-¢xed in cold
methanol for 10 min, washed, and treated with the second primary
antibody, RRG4, at 1:100 for 1 h. The sections were washed, treated
with the secondary antibody (rhodamine-labeled goat anti-rabbit IgG;
Sigma), and washed. Control sections were treated with the two sec-
ondary antibodies in a similar fashion. The sections were mounted in
Fluoromount-G (Southern Biotechnology Associates, Inc, Birming-
ham, AL, USA) and digitally photographed with a Zeiss photomicro-
scope III (Carl Zeiss, Oberkochen, Germany).
2.10. Co-immunoprecipitation of HRG4 and ARL2
The rat retinal extract was ¢rst pre-cleaned for use in immunopre-
cipitation. 50 Wl of pre-immune rabbit serum was added to 2.5 mg of
rat retinal extract, and the mixture was incubated for 1 h at 4‡C.
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18 mg of Protein A-Sepharose (Sigma) was added, and the mixture
was incubated for additional 30 min at 4‡C. The Protein A-Sepharose
complex was removed by centrifugation at 12 000Ug for 5 min at 4‡C,
and the supernatant was used for immunoprecipitation. The super-
natant was divided into two 250 Wl portions, 5 Wl of HRG4 antiserum
[2] was added to one portion, 5 Wl of pre-immune serum was added to
the other portion, both in NET gel bu¡er (50 mM Tris^HCl, pH 7.5,
150 mM NaCl, 0.1% (v/v) Nonidet P-40, 1 mM ethylenediamine tetra-
acetic acid (EDTA), pH 8.0, 0.25% (w/v) gelatin, 0.02% (v/v) sodium
azide), and the mixtures were incubated for 1 h at 4‡C. 15 mg of
Protein A-Sepharose was added to both, and the mixtures were incu-
bated for additional 1 h at 4‡C. The samples were centrifuged at
12 000Ug for 20 s to collect the immunoprecipitates which were
then washed three times with 1 ml each of PBS. The ¢nal samples
were subjected to Western blot analysis as described above with the
ARL2 and HRG4 antibodies.
2.11. Pull-down of ARL2 with HRG4
RRG4-GST hybrid protein and GST protein were prepared from
600 ml of bacterial cultures as previously described [2], and puri¢ed by
absorption to 300 Wl of glutathione-Sepharose. 35S-labeled ARL2-B42
hybrid protein was prepared by using 1 Wg of the ARL2-containing
pYESTrp2 yeast two-hybrid clone in an in vitro transcription^trans-
lation reaction in 40 Wl of TNT T7 Quick Master Mix (TNT Quick
Coupled Transcription/Translation Systems, Promega, Madison, WI,
USA) and 2 Wl (30 WCi) of [35S]methionine (Amersham) at 30‡C for 90
min. To 15 Wl each of the transcription^translation product containing
the 35S-labeled ARL2-B42 hybrid protein were added 35 Wg of RRG4-
GST-Sepharose or 35 Wg of GST-Sepharose, and the mixtures were
incubated at 4‡C overnight. The mixtures were centrifuged at 2000Ug
for 3 min, washed with PBS ¢ve times, resuspended in 50 Wl of PBS
containing 1 Wg/Wl aprotinin and 100 Wg/ml phenylmethylsulfonyl-
£uoride, and analyzed by SDS^PAGE and autoradiography.
3. Results
Clones from our human retinal cDNA library [8] were used
to construct the interactive trap cDNA library (prey library)
for the yeast two-hybrid strategy. A number of important
retina-speci¢c and -enriched clones has been isolated from
this library, indicating the suitability of this library for con-
struction of the prey library [1,8,10^12]. 80 000 primary clones
were obtained in the prey library with an average insert size of
1.7 kb. For the construction of the HRG4 bait strain, the
coding sequence of HRG4 was PCR-ampli¢ed, inserted into
the vector, con¢rmed by sequencing, and used for transfor-
mation of the L40 yeast strain. Expression of the LexA DNA-
binding domain-HRG4 hybrid protein by the transformant
was con¢rmed by Western blot analysis, and the histidine
auxotrophy and the absence of L-galactosidase activity were
also con¢rmed (data not shown).
A large-scale transformation of the L40 bait strain with 500
Wg of the prey library clones resulted in approximately 6 mil-
lion initial transformants (Fig. 1). 2.4 million transformants
were subjected to selection, ¢rst for histidine prototrophy and
zeocin resistance which yielded 572 colonies. A second selec-
tion for L-galactosidase activity and zeocin resistance resulted
in 13 colonies. The cDNA clones were extracted from the
positive colonies and sequenced for identi¢cation. In order
to rule out false positive clones, the L40 strain was trans-
formed with the putative positive clones, and tested for L-ga-
lactosidase expression after additional transformation with
various bait constructs (Fig. 2). Nine out of the 13 clones
showed strong L-galactosidase activity only after transforma-
tion with the correct HRG4 bait construct, indicating true
positivity. All nine clones contained the cDNA for ARL2.
In order to con¢rm the interaction of HRG4 with ARL2 in
the retina, we ¢rst demonstrated the presence of ARL2 in the
mammalian retina. Antibody against ARL2 was obtained
from two sources, one being a generous gift from Emory
University (Daniel Sharer) and the other being our own poly-
clonal antibody produced as described with recombinantly
expressed human ARL2. The speci¢city of our antibody ac-
tivity against ARL2 was con¢rmed by its inactivation with
excess antigen (data not shown). The two antibodies were
used in Western blot analysis of rat retinal protein extract.
Results demonstrated the presence of the 21 kDa ARL2 in the
retina (Fig. 3). Next, the speci¢c localization of ARL2 in the
retina in relation to HRG4 was determined by double immu-
no£uorescence. The ARL2 antibody showed reaction in var-
ious layers of the rat retina, namely the ganglion cell layer,
inner nuclear layer, outer plexiform layer (OPL), and the
photoreceptor inner segments (IS) (Fig. 4B). There was also
a low level of reaction present in the inner plexiform layer.
The HRG4 antibody showed reaction in the OPL as previ-
ously reported [2] and in the IS (Fig. 4C). Thus, the co-local-
ization of these two proteins in the OPL and IS was clearly
demonstrated, consistent with their interaction as revealed by
the yeast two-hybrid strategy. Controls using secondary anti-
bodies alone were negative (Fig. 4D, E).
Two approaches were used to directly demonstrate and
con¢rm the interaction between ARL2 and HRG4, i.e. co-
immunoprecipitation and direct binding of recombinantly ex-
6 million transformants by large-scale transformation
Screened 2.4 million transformants
572 His+ colonies
13 His+/LacZ+ colonies
Sequencing
X-gal
Selection (-HIs, +Zeocin)
Fig. 1. Summary of the isolation of HRG4-interacting proteins by
the yeast two-hybrid strategy.
Positive
clones
Positive plasmid
alone
Positive plasmid
+pHybLex/Zeo
Positive plasmid
+pHybLex/Zeo-HRG4
Positive plasmid
+pHybLex/Zeo-Lamin
1-46
8-16
10-4
Fig. 2. Test of putative positive clones for false positivity. The 13
putative positive clones obtained by the yeast two-hybrid strategy
(representative clones 1-46, 8-16, and 10-4 shown) were tested for
true positivity by transformation into L40 strain and the ¢lter lift
assay for L-galactosidase as is or after transformation with the bait
vector alone (pHybLex/Zeo), bait vector containing HRG4 (pHyb-
Lex/Zeo-HRG4), or bait vector containing lamin (pHybLex/Zeo-
lamin). The strong positive reaction for clone 10-4 is shown only in
the presence of the HRG4-containing bait.
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pressed proteins. HRG4 was immunoprecipitated from rat
retinal protein extract using anti-HRG4 serum and Protein
A, and co-precipitated proteins were analyzed by Western
blotting with the HRG4 and ARL2 antibody. ARL2 was
clearly demonstrated as a co-precipitated protein when anti-
HRG4 serum was used, but not when pre-immune serum was
used for the immunoprecipitation (Fig. 5). Finally in a direct
binding experiment, 35S-labeled ARL2-B42 activating domain
hybrid protein was expressed from the pYESTrp2 clone con-
taining the ARL2 cDNA. The RRG4-GST-glutathione-Seph-
arose complex was prepared by bacterial expression, and the
two were mixed and tested for binding. The 35S-labeled ARL2
hybrid protein was observed to bind the RRG4-GST hybrid
protein but not the GST protein alone (Fig. 6), again con¢rm-
ing the interaction of ARL2 and HRG4.
PDEN is a protein that was isolated from the soluble form
of PDE6, the rod-speci¢c cGMP phosphodiesterase complex
[13], and it shows homology to HRG4, especially in the
COOH terminal region (30% identity) [14]. Like HRG4,
PDEN also interacts with ARL2 [15]. Recently, the crystal
structure of the complex between PDEN and ARL2-GTP
was elucidated, and the amino acid residues in PDEN that
are important for its interaction with ARL2 were delineated
[16]. Alignment and comparison of the homologous regions of
the PDEN and HRG4 sequences demonstrated a high degree
of conservation of these residues in HRG4 (10 of 13 residues
(77%) identical or similar) (Fig. 7). A hydrophobic pocket has
been shown to be present in PDEN, and the residues that are
important for this pocket were also delineated [16]. Again,
Fig. 4. Double immuno£uorescence of rat retina with ARL2 and HRG4 antibodies. 5 months old rat retina was reacted with the human
ARL2 antibody at 1:50 and rat HRG4 (RRG4) antibody at 1:100 and visualized with FITC-conjugated secondary antibody and rhodamine-
conjugated secondary antibody, respectively. The micrographs of the phase (A), ARL2-reacted FITC (B), HRG4-reacted rhodamine (C), and
the controls for the FITC and rhodamine secondary antibodies (D, E) are shown. The ARL2 reaction is present predominantly in the ganglion
cell, inner nuclear, outer plexiform, and inner segment layers with low activity in the inner plexiform layer. HRG4 is present in the outer plexi-
form and inner segment layers. The co-localization of ARL2 and HRG4 in the outer plexiform and inner segment layers is demonstrated. The
FITC and rhodamine controls do not show any signi¢cant reaction in any of the layers. GCL, ganglion cell layer; IPL, inner plexiform layer;
INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner segment; OS, outer segment.
Fig. 3. Western blot analysis of rat retinal proteins with ARL2 anti-
bodies. 30 Wg of rat retinal proteins were Western blotted with two
di¡erent polyclonal antibodies against human ARL2. The blots
were reacted with A, no antibody; B, a⁄nity-puri¢ed polyclonal
ARL2 antibody from Emory University at 1:200; C, our a⁄nity-
puri¢ed polyclonal ARL2 antibody at 1:200. The 21 kDa ARL2
band (arrow) was visualized with both antibodies. The source of the
faint upper background bands is identi¢ed as non-speci¢c reaction
of the secondary antibody in lane A. Molecular sizes in kDa are
shown.
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there was signi¢cant conservation of these residues in HRG4
(11 of 17 residues (65%) identical or similar).
4. Discussion
This study demonstrates that HRG4, highly expressed in
retinal photoreceptor synapses, interacts with ARL2. The pre-
cise function of ARL2 is not yet known. Nevertheless, an
analysis of structurally similar proteins and other proteins
found to interact with ARL2 may provide insight into the
function of the HRG4^ARL2 interaction.
ADP-ribosylation factors (ARFs) are ubiquitous, highly
conserved, Ras-like GTP-binding proteins [17,18]. The func-
tion of ARFs, consisting of at least six di¡erent genes/pro-
teins, was originally demonstrated to be a cofactor activity of
ADP-ribosylation of GKS by bacteria toxins [19], but it has
since expanded to include vesicular tra⁄c [20^23], comple-
mentation of an arf1^arf1 double deletion in Saccharomyces
cerevisiae [24,25], and activation of phospholipase D [26,27].
ARF-like proteins (ARLs) are more structurally divergent
proteins that are 40^60% homologous to ARFs or to each
other. At least 10 distinct ARLs have been identi¢ed [28^
32]. The ARLs lack the speci¢c functions that have been de-
scribed for the ARFs, with exception of ADP-ribosylation
factor-like protein 1 (ARL1) showing similarity to ARFs in
its e¡ect on the Golgi and some of its interacting proteins
[15,33].
ARL2 is 45% homologous to ARF1 and unique among the
human PDEδ
human HRG4
human PDEδ
human HRG4
human PDEδ
human HRG4
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RV--PKKILKCKAVSRELNFSSTEQ-MEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNT
RYQFTPAFLRLRQVGATVEFTVGDKPVNNFRMIERHYFRNQLLKSFDFHFGFCIPSSKNT
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Fig. 7. Homology between human PDEN and HRG4 and conservation of residues important for the interaction with ARL2 and the hydropho-
bic pocket. The alignment of the human PDEN and HRG4 amino acid sequences in the homologous region as determined by the FASTA pro-
gram (GCG, Madison, WI, USA) is shown. This region shows an identity of 23% in 153 amino acid residues between the two sequences. Resi-
dues identical between the two sequences in the alignment are designated by bars, and residues that are similar (conservative changes) are
designated by colons. Amino acid residues that have been determined to be at the interface of interaction between PDEN and ARL2 are desig-
nated by asterisks above them, and residues shown to be important for the formation of a hydrophobic pocket in PDEN are designated by plus
symbols above them [16]. A signi¢cant number of both types of residues are conserved in HRG4; of the 13 residues important for interaction
with ARL2 (*), eight are identical and two are similar, and for 17 residues important for the hydrophobic pocket (+), three are identical and
eight are similar.
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Fig. 5. Co-immunoprecipitation of ARL2 with HRG4 in rat retinal
extract. Rat retinal extract was treated with antiserum against
HRG4 or pre-immune serum and Protein A-Sepharose, and the pre-
cipitated complex was Western blotted with HRG4 and ARL2 anti-
bodies. A, precipitated with HRG4 antiserum and Western blotted
with HRG4 antibody. B, precipitated with HRG4 antiserum and
Western blotted with ARL2 antibody. C, precipitated with pre-im-
mune serum and Western blotted with HRG4 and ARL2 antibody
(no reaction seen with either). Immunoprecipitation of HRG4
(upper arrow, A) and co-precipitation of the bound ARL2 (lower
arrow, B) are shown. Superimposition of the ARL2 and antibody
light chain signals was con¢rmed by densitometry. Upper asterisk,
antibody heavy chain; lower asterisk, antibody light chain. Molecu-
lar sizes in kDa are shown.
kDa
40
31
A B C
Fig. 6. Pull-down of 35S-labeled ARL2-B42 hybrid protein with
HRG4-GST-glutathione-Sepharose. 35S-labeled ARL2-B42 hybrid
protein expressed from the positive pYESTrp2 clone was mixed
with HRG4-GST-glutathione-Sepharose or GST-glutathione-Sepha-
rose, and the interaction between the two was examined after centri-
fugation by electrophoresis and autoradiography. A, original 35S-la-
beled ARL2-B42 hybrid protein. B, mixed with HRG4-GST-
glutathione-Sepharose and analyzed. C, mixed with GST-gluta-
thione-Sepharose and analyzed. Binding of the ARL2-B42 hybrid
protein (arrow) to the HRG4-GST complex (B) but not to the GST
complex (C) is shown. Molecular sizes in kDa are shown.
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ARF/ARLs in its high a⁄nity for GTP and GDP and its lack
of N-myristoylation which is present in all the other members
of the ARF family [29,34]. It is expressed ubiquitously like the
ARFs, but is most abundant in neural tissue. The precise
function of ARL2 and the other ARLs is not yet known,
but there have been some interesting recent reports. Alp41,
a yeast ortholog of ARL2, has been shown to play an impor-
tant role in the assembly of tubulin to form microtubules [35].
Speci¢cally, Alp41 was shown to act upstream of cofactor D
in the K-tubulin pathway, and to be essential for the viability
of ¢ssion yeast. ARL2 was actually shown to interact with
cofactor D and prevent the destruction of tubulin and micro-
tubules mediated by cofactor D [36]. TITAN5, a gene in Ara-
bidopsis important for cytokinesis and proposed to regulate
microtubule function in seed development, was also found to
be the plant ortholog of ARL2, consistent with its involve-
ment in microtubule formation [37,38]. A 19 kDa protein
named binder of ARL2 (BART) was found to interact with
ARL2 by a GTPase overlay strategy and was determined to
be the ¢rst identi¢ed e¡ector for ARL2 [39]. More recently,
the BART-ARL2-GTP complex was shown to enter the mi-
tochondria and bind the adenine nucleotide transporter 1
(ANT1) [34]. The ANT proteins are integral inner membrane
proteins of mitochondria that form channels used in exchange
of ATP and ADP, thus controlling the ATP level in the cy-
toplasm [40]. Besides BART, additional proteins have been
shown to interact with ARL2 by the yeast two-hybrid strategy
[15]. Eight overlapping di¡erent binding partners of ARL1,
ARL2, and ARL3 were identi¢ed, including HRG4, BART,
and PDEN for ARL2. Thus, the identi¢cation of HRG4 as an
ARL2-binding protein was consistent with our result.
Because the precise function of ARL2 is not yet known, the
functional signi¢cance of the interaction of HRG4 with ARL2
remains to be determined. Since HRG4 is found in the photo-
receptor synapse and would be expected to be present in the
photoreceptor axon as well, the involvement of ARL2 in tu-
bulin assembly and microtubule formation suggests that
HRG4 may be involved in microtubule formation in the pho-
toreceptor axon and synapse via ARL2. Microtubules are
important for vesicular transport of proteins in axons and
synapses. Thus, HRG4 may have a role in regulating vesicle
tra⁄cking of proteins. Interestingly, another protein related to
retinal degeneration, the retinitis pigmentosa protein 2 (RP2),
is similar to the tubulin-speci¢c chaperone cofactor C and has
been shown to interact with ADP-ribosylation factor-like pro-
tein 3, ARL3 [41]. RP2 was shown to be a tubulin GTPase
activator, thus possibly playing a role in the regulation of
microtubule dynamics which may be a common theme in
retinal degeneration. As for a possible relationship to mito-
chondria, as in the case of BART interacting with ARL2,
immunocytochemical analysis of HRG4 did not reveal any
obvious association with the mitochondria in synapses, but
further investigation is necessary to answer this question fully
[2].
The recently demonstrated interaction of PDEN with ARL2
provides an interesting possibility for the function of HRG4.
PDEN, in addition to being a binding partner of ARL2 like
HRG4, is homologous to HRG4. The two proteins are 23%
identical overall, and 30% identical in the COOH-terminal 1/3
[14]. PDEN is expressed ubiquitously, whereas HRG4 is pre-
dominantly expressed in the photoreceptors [1,42]. PDEN was
originally isolated from the soluble form of PDE6, the rod-
speci¢c cGMP phosphodiesterase, but was found not to a¡ect
the catalytic activity of the enzyme [13,42]. Rather, it was
found to bind the K and L subunits of PDE6 by their preny-
lated COOH ends and to solubilize them from the photore-
ceptor membrane [42]. PDEN has also been shown to interact
with and solubilize Rab 13, a small GTPase, involved in mem-
brane tra⁄cking in ¢broblasts [43]. PDEN also interacts with
the retinitis pigmentosa GTPase regulator (RPGR), the
pathogenic gene for X-linked retinitis pigmentosa, RP3 [44].
The amino-terminal half of RPGR is homologous to regulator
of chromosome condensation (RCC1), which is essential for
nucleo-cytoplasmic transport [45,46]. Cumulatively, these re-
sults point to a pattern of involvement of PDEN in intracel-
lular protein transport and localization.
The crystal structure of the complex between PDEN and
ARL2-GTP was recently elucidated, and the amino acid res-
idues in PDEN that are involved in its interaction with ARL2
were delineated [16]. Importantly, there is a high degree of
conservation of these residues in HRG4 (10 of 13 residues
(77%) identical or similar), suggesting that the molecular na-
ture of the interaction between HRG4 and ARL2 may be very
similar to that between PDEN and ARL2 (Fig. 7). A hydro-
phobic pocket has been shown to be important in PDEN for
the binding of prenylated proteins, such as the subunits of
PDE6, and the residues that are important for this pocket
were also delineated [16]. Again, there is signi¢cant conserva-
tion of these residues in HRG4 (11 of 17 residues (65%) iden-
tical or similar), suggesting that HRG4 may also have such a
hydrophobic pocket that may play a role in binding preny-
lated proteins (Fig. 7). Based on the ¢ndings, PDEN was sug-
gested to be a soluble transport factor for certain prenylated
proteins which is mediated by interaction with ARL2-GTP
[16]. HRG4 was shown not to be able to extract PDE6
from the photoreceptor outer segment membrane [47], but it
may play a role in the insertion/extraction of some other
membrane protein. Because of its association with synaptic
vesicles, it is tempting to speculate that HRG4 may be in-
volved in the membrane tra⁄cking of certain synaptic vesicle
proteins. Interestingly, we demonstrated a speci¢c decrease in
the levels of several peripheral membrane proteins of photo-
receptor synaptic vesicles in a transgenic model expressing the
identical truncation mutation of HRG4 as found in a human
patient with late-onset cone^rod dystrophy [5]. This phenom-
enon may be consistent with HRG4 playing a role in mem-
brane tra⁄cking of photoreceptor synaptic vesicle proteins.
Whether HRG4 has such a function will be determined
through further investigation of HRG4 in vitro.
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